533 related articles for article (PubMed ID: 11742186)
1. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
Naesdal J; Wilson I
Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
[TBL] [Abstract][Full Text] [Related]
2. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
4. Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion.
Maetzel A
Can J Gastroenterol; 2003 May; 17(5):335-8. PubMed ID: 12772009
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
7. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs.
Graham DY
Am J Med; 2001 Jan; 110(1A):58S-61S. PubMed ID: 11166000
[TBL] [Abstract][Full Text] [Related]
8. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
[TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal anti-inflammatory drugs.
Tseng CC; Wolfe MM
Med Clin North Am; 2000 Sep; 84(5):1329-44. PubMed ID: 11026931
[TBL] [Abstract][Full Text] [Related]
10. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
Ballinger A; Smith G
Expert Opin Pharmacother; 2001 Jan; 2(1):31-40. PubMed ID: 11336566
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
12. Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression.
Lad R; Armstrong D
Can J Gastroenterol; 1999 Mar; 13(2):135-42. PubMed ID: 10203432
[TBL] [Abstract][Full Text] [Related]
13. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
Chan FK; Graham DY
Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
[TBL] [Abstract][Full Text] [Related]
14. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
15. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
;
Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
[TBL] [Abstract][Full Text] [Related]
16. [Prophylaxis and therapy of gastropathy caused by non-steroidal anti-inflammatory drugs].
László A
Orv Hetil; 2002 Jul; 143(27):1643-8. PubMed ID: 12180001
[TBL] [Abstract][Full Text] [Related]
17. COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Cryer B
Gastroenterology; 2004 Oct; 127(4):1256-8. PubMed ID: 15481002
[No Abstract] [Full Text] [Related]
18. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage.
Singh G; Triadafilopoulos G
Int J Clin Pract; 2005 Oct; 59(10):1210-7. PubMed ID: 16178990
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.
La Corte R; Caselli M; Castellino G; Bajocchi G; Trotta F
Drug Saf; 1999 Jun; 20(6):527-43. PubMed ID: 10392669
[TBL] [Abstract][Full Text] [Related]
20. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]